Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

Healthcare Deals This Week: Merck, Space Meds and More No Photo Available

Yeji Jesse Lee

Healthcare companies were busy in the days following the long weekend, with a flurry of deal announcements from big and small names al... (more story)

Decades After Autism Omnibus, CDC Back In Thimerosal Fight No Photo Available

Dan McKay

An unusual legal proceeding two decades ago tested claims that childhood vaccines caused autism. The "omnibus" proceeding found no suc... (more story)

How Healthcare Should Measure Its Return On AI Investment No Photo Available

Yeji Jesse Lee

As the healthcare industry moves to embrace artificial intelligence, a key question is shaping which AI companies get funding and part... (more story)